Author

Dave Smart

Observed names: D. Smart, Smart, Dave

Observed institution: Philip Morris International (Switzerland)

OpenAlex ID: A5073656546

Delivering the precision oncology paradigm: reduced R&D costs and greater return on investment through a companion diagnostic informed precision oncology medicines approach

2023 · Raymond H. Henderson, Declan French, et al. · Journal of Pharmaceutical Policy and Practice · 27

Cost‐effectiveness of precision diagnostic testing for precision medicine approaches against non‐small‐cell lung cancer: A systematic review

2021 · Raymond Henderson, Peter Keeling, et al. · Molecular Oncology · 24

Significant decline in cancer diagnostic testing in U.S. CMS population during the COVID-19 pandemic.

2021 · Dave Smart, Peter Riccelli, et al. · Journal of Clinical Oncology · 2

Use of molecular NGS vs single gene testing differs by clinical setting and physician’s specialty in mNSCLC management.

2023 · Katherine Elizabeth Keating, Rachael Victoria Hewitt, et al. · Journal of Clinical Oncology · 1

Economic burden of not testing for FLT3 to treat acute myeloid leukemia.

2020 · Raymond Henderson, Dave Smart, et al. · Journal of Clinical Oncology · 1

Effect of COVID-19 Pandemic Control Measures on Diagnoses of Hematologic Cancer Among CMS Population in 2020

2021 · Dave Smart, Wendy Moore, et al. · Blood

Does the precision oncology medicine development pathway deliver value for health systems?

2021 · Raymond Henderson, Declan French, et al. · Journal of Clinical Oncology

P37.33 A look at EGFR, ALK, and PD-L1 Biomarker Test Availability, Adoption, and Test Ordering Behavior at Diagnosis of NSCLC in the United States

2021 · J. Sornkom, P. Riccelli, et al. · Journal of Thoracic Oncology

Stability of rare TP53 co-mutations in AML patients.

2020 · Kenneth Joel Bloom, Adam Idica, et al. · Journal of Clinical Oncology

Pcn60 Cost-effectiveness of Precision Diagnostic Testing and Precision Medicine for Non-small Cell Lung Cancer: a Systematic Review

2020 · R. Henderson, M. Lawler, et al. · Value in Health

Real world patient numbers for AML targeted therapies.

2017 · Marcos Tadeu dos Santos, Dave Smart, et al. · Journal of Clinical Oncology

Genomic analysis of L5178Y tk+/− cells and their induced tk−/− mutant colonies

2016 · J.N. Battey, D. Smart, et al. · Toxicology Letters

Works count: 14

Citation count: 55

H-index: 2

I10-index: 2